164 related articles for article (PubMed ID: 37937645)
1. Preliminary results of the European multicentric phase III trial regarding sirolimus in slow-flow vascular malformations.
Seront E; Van Damme A; Legrand C; Bisdorff-Bresson A; Orcel P; Funck-Brentano T; Sevestre MA; Dompmartin A; Quere I; Brouillard P; Revencu N; De Bortoli M; Hammer F; Clapuyt P; Dumitriu D; Vikkula M; Boon LM
JCI Insight; 2023 Nov; 8(21):. PubMed ID: 37937645
[TBL] [Abstract][Full Text] [Related]
2. Treatment of voluminous and complicated superficial slow-flow vascular malformations with sirolimus (PERFORMUS): protocol for a multicenter phase 2 trial with a randomized observational-phase design.
Maruani A; Boccara O; Bessis D; Guibaud L; Vabres P; Mazereeuw-Hautier J; Barbarot S; Chiaverini C; Blaise S; Droitcourt C; Mallet S; Martin L; Lorette G; Woillard JB; Jonville-Bera AP; Rollin J; Gruel Y; Herbreteau D; Goga D; le Touze A; Leducq S; Gissot V; Morel B; Tavernier E; Giraudeau B;
Trials; 2018 Jun; 19(1):340. PubMed ID: 29945674
[TBL] [Abstract][Full Text] [Related]
3. Sirolimus is efficacious in treatment for extensive and/or complex slow-flow vascular malformations: a monocentric prospective phase II study.
Hammer J; Seront E; Duez S; Dupont S; Van Damme A; Schmitz S; Hoyoux C; Chopinet C; Clapuyt P; Hammer F; Vikkula M; Boon LM
Orphanet J Rare Dis; 2018 Oct; 13(1):191. PubMed ID: 30373605
[TBL] [Abstract][Full Text] [Related]
4. Sirolimus (Rapamycin) for Slow-Flow Malformations in Children: The Observational-Phase Randomized Clinical PERFORMUS Trial.
Maruani A; Tavernier E; Boccara O; Mazereeuw-Hautier J; Leducq S; Bessis D; Guibaud L; Vabres P; Carmignac V; Mallet S; Barbarot S; Chiaverini C; Droitcourt C; Bursztejn AC; Lengellé C; Woillard JB; Herbreteau D; Le Touze A; Joly A; Léauté-Labrèze C; Powell J; Bourgoin H; Gissot V; Giraudeau B; Morel B
JAMA Dermatol; 2021 Nov; 157(11):1289-1298. PubMed ID: 34524406
[TBL] [Abstract][Full Text] [Related]
5. Clinical differences in sirolimus treatment with low target levels between children and adults with vascular malformations - A nationwide trial.
Harbers VEM; Zwerink LGJM; Rongen GA; Klein WM; van der Vleuten CJM; van Rijnsoever IMP; Gerdsen-Drury L; Flucke UE; Verhoeven BH; de Laat PCJ; van der Horst CMAM; Schultze Kool LJ; Te Loo DMWM
Clin Transl Sci; 2023 May; 16(5):781-796. PubMed ID: 36824030
[TBL] [Abstract][Full Text] [Related]
6. A narrative review of the role of sirolimus in the treatment of congenital vascular malformations.
Geeurickx M; Labarque V
J Vasc Surg Venous Lymphat Disord; 2021 Sep; 9(5):1321-1333. PubMed ID: 33737259
[TBL] [Abstract][Full Text] [Related]
7. Single Center Experience of Sirolimus Therapy in Head and Neck Low-flow Vascular Malformations.
Pang C; Evans N; Jethwa P; Papadopoulou A; Khalifa M; Tsui J; Hamilton G; Lim CS; Brookes J
Vasc Endovascular Surg; 2021 Jul; 55(5):482-490. PubMed ID: 33878964
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of oral sirolimus for high-flow vascular malformations in real clinical practice.
Durán-Romero AJ; Hernández-Rodríguez JC; Ortiz-Álvarez J; Domínguez-Cruz JJ; Monserrat-García MT; Conejo-Mir Sánchez J; Bernabeu-Wittel J
Clin Exp Dermatol; 2022 Jan; 47(1):57-62. PubMed ID: 34240451
[TBL] [Abstract][Full Text] [Related]
9. A prospective multicenter study of sirolimus for complicated vascular anomalies.
Ji Y; Chen S; Yang K; Zhou J; Zhang X; Jiang X; Xu X; Lu G; Qiu L; Kong F; Zhang Y
J Vasc Surg; 2021 Nov; 74(5):1673-1681.e3. PubMed ID: 34082006
[TBL] [Abstract][Full Text] [Related]
10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
11. New and Emerging Targeted Therapies for Vascular Malformations.
Van Damme A; Seront E; Dekeuleneer V; Boon LM; Vikkula M
Am J Clin Dermatol; 2020 Oct; 21(5):657-668. PubMed ID: 32557381
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of sirolimus in the treatment of vascular malformations: A protocol for systematic review and meta-analysis.
Dong J; Han D; Wang D; Lu H; Wang X
Medicine (Baltimore); 2020 Oct; 99(40):e22596. PubMed ID: 33019479
[TBL] [Abstract][Full Text] [Related]
13. Real-World Data on the Use of Sirolimus in Asian Children with Vascular Malformations.
Yu L; Xu Z; Wei L; Zhang B; Qiu L; Ma L; Li L
Paediatr Drugs; 2024 May; 26(3):309-317. PubMed ID: 38280106
[TBL] [Abstract][Full Text] [Related]
14. Topical sirolimus 0.1% for treating cutaneous microcystic lymphatic malformations in children and adults (TOPICAL): protocol for a multicenter phase 2, within-person, randomized, double-blind, vehicle-controlled clinical trial.
Leducq S; Caille A; Barbarot S; Bénéton N; Bessis D; Boccara O; Bursztejn AC; Chiaverini C; Dompmartin A; Droitcourt C; Gissot V; Goga D; Guibaud L; Herbreteau D; Le Touze A; Léauté-Labrèze C; Lorette G; Mallet S; Martin L; Mazereeuw-Hautier J; Phan A; Plantin P; Quéré I; Vabres P; Bourgoin H; Giraudeau B; Maruani A;
Trials; 2019 Dec; 20(1):739. PubMed ID: 31847908
[TBL] [Abstract][Full Text] [Related]
15. Patients with Congenital Low-Flow Vascular Malformation Treated with Low Dose Sirolimus.
Harbers VEM; Rongen GAPJM; van der Vleuten CJM; Verhoeven BH; de Laat PCJ; van der Horst CMAM; Klein WM; Schultze Kool LJ; Loo DMWMT
Adv Ther; 2021 Jun; 38(6):3465-3482. PubMed ID: 34003452
[TBL] [Abstract][Full Text] [Related]
16. Effect of sirolimus on coagulopathy of slow-flow vascular malformations.
Mack JM; Verkamp B; Richter GT; Nicholas R; Stewart K; Crary SE
Pediatr Blood Cancer; 2019 Oct; 66(10):e27896. PubMed ID: 31250546
[TBL] [Abstract][Full Text] [Related]
17. Identification of autosomal cis expression quantitative trait methylation (cis eQTMs) in children's blood.
Ruiz-Arenas C; Hernandez-Ferrer C; Vives-Usano M; Marí S; Quintela I; Mason D; Cadiou S; Casas M; Andrusaityte S; Gutzkow KB; Vafeiadi M; Wright J; Lepeule J; Grazuleviciene R; Chatzi L; Carracedo Á; Estivill X; Marti E; Escaramís G; Vrijheid M; González JR; Bustamante M
Elife; 2022 Mar; 11():. PubMed ID: 35302492
[TBL] [Abstract][Full Text] [Related]
18. A xenograft model for venous malformation.
Goines J; Li X; Cai Y; Mobberley-Schuman P; Metcalf M; Fishman SJ; Adams DM; Hammill AM; Boscolo E
Angiogenesis; 2018 Nov; 21(4):725-735. PubMed ID: 29786783
[TBL] [Abstract][Full Text] [Related]
19. Sirolimus for the treatment of complicated vascular anomalies in children.
Hammill AM; Wentzel M; Gupta A; Nelson S; Lucky A; Elluru R; Dasgupta R; Azizkhan RG; Adams DM
Pediatr Blood Cancer; 2011 Dec; 57(6):1018-24. PubMed ID: 21445948
[TBL] [Abstract][Full Text] [Related]
20. Sirolimus for the treatment of children with various complicated vascular anomalies.
Lackner H; Karastaneva A; Schwinger W; Benesch M; Sovinz P; Seidel M; Sperl D; Lanz S; Haxhija E; Reiterer F; Sorantin E; Urban CE
Eur J Pediatr; 2015 Dec; 174(12):1579-84. PubMed ID: 26040705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
